NEPHROPLUS
Nephrocare Health Services Limited
Nephrocare Health Services Limited (NEPHROPLUS) Stock Analysis & Case Study
Is NEPHROPLUS a good buy? The data-driven verdict.
Nephrocare Health Services Limited (NEPHROPLUS) trades at ₹694,on the numbers it tread carefully, a Downstox Snapshot Score of 33/100.
On the numbers, Nephrocare Health Services Limited (NEPHROPLUS) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 93.2× earnings, ROE of 8.8%. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
NEPHROPLUS fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How NEPHROPLUS ranks against the 2,373 companies in our screener
- NEPHROPLUS's market cap of 6,980 Cr ranks in the 70th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- NEPHROPLUS's book value of ₹111 ranks in the 55th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- NEPHROPLUS's promoter holding of 63.8% ranks in the 60th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- NEPHROPLUS's 3-year profit (PAT) growth of 103.0% ranks in the 94th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- NEPHROPLUS's 3-year revenue growth of 32.0% ranks in the 87th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- NEPHROPLUS's debt-to-equity ratio of 0.07x is lower than 82% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is NEPHROPLUS overvalued? NEPHROPLUS P/E vs peers
NEPHROPLUS trades at 93.2× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
The bull case for NEPHROPLUS
- Nephrocare Health Services Limited is part of the nifty500 universe with live, tracked fundamentals on Downstox.
The bear case & risks
- NEPHROPLUS's P/E of 93.2x is lower than 12% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- NEPHROPLUS's return on equity of 8.8% ranks in the 43rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
NEPHROPLUS Piotroski F-Score: 5/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. NEPHROPLUS scores 5/8, mixed financial health.
NEPHROPLUS MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy NEPHROPLUS with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.00% | 2.9× |
| Zerodha | 30.46% | 3.3× |
| Groww | 30.50% | 3.3× |
| Dhan | 30.46% | 3.3× |
| Kotak Neo | 100.00% | 1.0× |
| Paytm Money | 30.53% | 3.3× |
| PocketfulCHEAPEST | 30.24% | 3.3× |
| Fyers | 31.25% | 3.2× |
| Anand Rathi | 30.46% | 3.3× |
| Share India | 30.43% | 3.3× |
Compare every broker on the NEPHROPLUS MTF page.
About Nephrocare Health Services Limited: sector, index & market-cap context
Nephrocare Health Services Limited (NEPHROPLUS) is a small-cap NSE-listed company, with a market capitalisation of ₹6,980 Cr. See more stocks on our screener.
How the NEPHROPLUS Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Nephrocare Health Services Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
NEPHROPLUS analysis, FAQs
Is Nephrocare Health Services Limited (NEPHROPLUS) a good buy?
On the numbers, Nephrocare Health Services Limited (NEPHROPLUS) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 93.2× earnings, ROE of 8.8%. This is a data snapshot for research, not investment advice.
Is NEPHROPLUS overvalued or undervalued?
NEPHROPLUS trades at 93.2× earnings, expensive versus the ~22× long-run Nifty average.
What is the bull case for NEPHROPLUS?
Nephrocare Health Services Limited is part of the nifty500 universe with live, tracked fundamentals on Downstox.
What are the risks in NEPHROPLUS?
NEPHROPLUS's P/E of 93.2x is lower than 12% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. NEPHROPLUS's return on equity of 8.8% ranks in the 43rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.